Skip to search formSkip to main contentSkip to account menu

denosumab

Known as: Denosumab [Chemical/Ingredient], Densosumab 
A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity… 
National Institutes of Health

Related topics

Related topics

11 relations
1 ML denosumab 60 MG/ML Prefilled Syringe [Prolia]1.7 ML denosumab 70 MG/ML Injection [Xgeva]In BloodNCIt Antineoplastic Agent Terminology

Narrower (3)

AMG 162ProliaXgeva

Broader (1)

Bone Density Conservation Agents

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
A review of the mechanism of action and clinical applications of sorafenib in advanced osteosarcoma
Review
2016
Review
2016
Monoclonal antibodies - A new era in the treatment of multiple myeloma.
Review
2016
Review
2016
Treatment of Paget’s Disease of Bone with Denosumab: Case Report and Literature Review
Paget’s disease is a condition involving focal overactivity of bone cells (osteoblasts and osteoclasts), which can result in… 
2015
2015
Anti-RANKL treatment improves screw fixation in cancellous bone in rats.
Review
2015
Review
2015
Emerging therapies in bone metastasis.
2014
2014
MRI osteitis predicts cartilage damage at the wrist in RA: a three-year prospective 3T MRI study examining cartilage damage
IntroductionCartilage damage impacts on patient disability in rheumatoid arthritis (RA). The aims of this magnetic resonance… 
Review
2013
Review
2013
A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer
Review
2012
Review
2012
The development of denosumab for the treatment of diseases of bone loss and cancer‐induced bone destruction
Denosumab is a fully human monoclonal antibody against RANK ligand (RANKL), an essential cytokine for the formation, function… 
2010
2010
New molecular targets in bone metastases
a Medical Oncology Dept, University Campus Bio-Medico, Rome, Italy b Medical Oncology Unit, IRCCS Casa Sollievo della Sofferenza… 
2008
2008
Inhibition of RANK/RANKL signal transduction pathway: a promising approach for osteoporosis treatment.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)